Merck KGaA appoints Kley

Merck KGaA has announced the appointment of a new executive board deputy chairman following the appointment of Dr Michael Roemer as chairman of the board.

Dr Karl-Ludwig Kley will fill the position vacated by Dr Roemeer in November last year, effective from September 1st 2006, joining from his current role at Deutsche Lufthansa AG.

He has also been approved as a general partner of E Merck OHG, which oversees the 73 per cent of the shares that are held in Merck KGaA by the Merck family.

“With his extensive background in the pharmaceuticals industry as well as his experience in responsible positions at two leading German companies, Dr Kley ? unlike anyone else ? is well equipped to create a major German pharmaceuticals and chemicals company,” said Dr Frank Stangenberg-Haverkamp, chairman of the advisory board of E Merck OHG.

“We, in conjunction with the executive board, agreed on Dr Kley also because his participation on the supervisory board guarantees the continuation of the current successful course on which Merck KGaA is proceeding.”

Previously, Dr Kley has worked for Bayer, leading sales across Africa, Asia and Latin America before going on to be responsible for corporate finance and investor relations.

© Adfero Ltd